Trend
DailyDowntrend (starting)
4 hourSymmetric Triangle
1 hourBearish
15 minSymmetric Triangle
5 minStrong Bearish
Daily trend turns up above $42.50
Key levels
Resistance$42.50
Support$37.97
Support$35.56
Latest news & SEC filings
AnalystHC Wainwright keeps Buy rating on Roivant Sciences, lifts target to $48
EarningsRoivant Sciences holds Q2 2027 earnings call
SEC FilingRoivant Sciences Ltd. filed a report on a major company event (Form 8-K)
All ROIV news →Roivant Sciences develops and commercializes prescription medicines, organizing its work through separate subsidiaries it calls Vants. Its drug pipeline features brepocitinib for dermatomyositis and other inflammatory conditions, IMVT-1402 for autoimmune disorders, and mosliciguat for a form of pulmonary hypertension. The company also backs early-stage drug discovery ventures and healthcare technology businesses. Its operations are based primarily in the United States.
Based on the company's 10-K filed May 20, 2026.
Nasdaq · Healthcare
SEPT Low Target
$41.00
SEPT Mid Target
$51.00
SEPT High Target
$56.00
Analyst Consensus
$51.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ROIV.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$51.00
12
Moat Score
NONE
1/9
Piotroski Score
39.5
Altman Z-Score
Insider Signal
SELLING
0 buys / 6 sells (90d)
Congress Signal
BUYING
2 buys / 2 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Venker Eric | officer | Sale | 200,000 | $7.3M | Nov 3, 2026 |
| Venker Eric | officer | Sale | 200,000 | $7.3M | Oct 28, 2026 |
| MOMTAZEE JAMES C | director | Buy | 383 | - | Oct 23, 2026 |
| MOMTAZEE JAMES C | director | Sale | 77 | $3K | Oct 23, 2026 |
| Epperly Melissa B, | director | Buy | 513 | - | Oct 23, 2026 |
| Epperly Melissa B, | director | Sale | 116 | $4K | Oct 23, 2026 |
| Oren Ilan | director | Buy | 810 | - | Oct 23, 2026 |
| Venker Eric | officer | Sale | 185,856 | $6.5M | Oct 20, 2026 |
| Venker Eric | officer | Sale | 14,144 | $501K | Oct 20, 2026 |
| Sukhatme Mayukh | director officer | Sale | 19,976 | $670K | Oct 16, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
-71.6%
3yr Revenue CAGR
-36.0%
EPS Growth YoY
-125%
FCF Growth YoY
10.1%
Revenue Trend
DECLINING
SEPT Investing tracks real-time dark pool institutional trades for ROIV, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 17:49:56 | $40.67 | 1,300 | $$53K | MIDPOINT |
| 17:46:45 | $40.64 | 1,300 | $$53K | BUY |
| 17:42:00 | $40.67 | 1,700 | $$69K | MIDPOINT |
| 17:39:33 | $40.67 | 1,800 | $$73K | MIDPOINT |
| 17:39:03 | $40.67 | 4,519 | $$184K | SELL |
5 dark pool trades shown · $$432K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT Investing provides real-time options flow tracking for ROIV, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $37 | Nov 20 | 8 | $$6400 | 16 | SWEEP |
1 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Roivant Sciences Ltd. (ROIV) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Roivant Sciences Ltd. (ROIV) is at $40.70, down 2.75% (-$1.15) at the Nov 12, 2026 close.
Latest ROIV news — Nov 10, 2026: HC Wainwright keeps Buy rating on Roivant Sciences, lifts target to $48 · Nov 9, 2026: Roivant Sciences holds Q2 2027 earnings call
Roivant Sciences shares closed at $40.67, up 3.04% on the day, trading between a low of $39.22 and a high of $41.43 on volume of 11.6 million shares. The move came as the company held its second-quarter 2027 earnings call and filed a Form 8-K reporting a major company event.
The average analyst price target for ROIV is $51.00, ranging from $41 to $56, based on 7 analysts. Latest: Citigroup maintains on Oct 28, 2026.
Analyst ratings for ROIV: 0 Buy, 13 Hold, 1 Sell — consensus Hold.
ROIV last reported on Aug 6, 2026: EPS -$0.33 vs -$0.30 expected — a miss of 10.1%.
ROIV does not currently pay a dividend.
Support: $37.97, $35.56, $33.00. Resistance: $42.50.
Insider activity: SELLING, 0 buys and 6 sells in the last 90 days.
Nov 10, 2026: HC Wainwright keeps Buy rating on Roivant Sciences, lifts target to $48 · Nov 9, 2026: Roivant Sciences holds Q2 2027 earnings call · Nov 9, 2026: Roivant Sciences Ltd. filed a report on a major company event (Form 8-K)